Key Takeaways & Executive Findings
- •• Gastrodia elata extract significantly reduces airway inflammation in OVA-induced allergic asthma mice. • GE extract attenuates airway remodeling, including goblet cell hyperplasia and collagen deposition. • The anti-inflammatory effects are associated with downregulation of Th2 cytokines and TGF-β1. • GE extract inhibits NF-κB and STAT3 signaling pathways, providing a molecular mechanism for its therapeutic effects.
Abstract
Background: Gastrodia elata (GE), a traditional Chinese medicine, has been reported to possess anti-inflammatory properties. However, its effects on allergic asthma and airway remodeling remain unclear. Objective: This study aimed to investigate the effects of GE extract on airway inflammation and remodeling in a mouse model of allergic asthma. Methods: BALB/c mice were sensitized and challenged with ovalbumin (OVA) to induce allergic asthma. Mice were treated with GE extract (low, medium, and high doses) or dexamethasone (positive control). Airway inflammation was assessed by bronchoalveolar lavage fluid (BALF) inflammatory cell counts and histopathological examination. Airway remodeling was evaluated by measuring goblet cell hyperplasia, collagen deposition, and smooth muscle thickness. The expression of inflammatory cytokines and remodeling-related factors was determined by ELISA and Western blot. Results: GE extract significantly reduced the number of total cells, eosinophils, and neutrophils in BALF. Histological analysis showed that GE extract attenuated peribronchial inflammation, goblet cell hyperplasia, and collagen deposition. Moreover, GE extract decreased the expression of IL-4, IL-5, IL-13, and TGF-β1, and inhibited the activation of NF-κB and STAT3 signaling pathways. Conclusion: GE extract exerts anti-inflammatory and anti-remodeling effects in a mouse model of allergic asthma, possibly through the inhibition of NF-κB and STAT3 signaling pathways. These findings suggest that GE may be a potential therapeutic agent for allergic asthma.
1. Introduction
Allergic asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness, inflammation, and remodeling. The prevalence of asthma has increased worldwide, and current treatments, such as corticosteroids, have limitations due to side effects and resistance. Therefore, there is a need for alternative therapeutic agents with fewer side effects. Gastrodia elata (GE), a traditional Chinese medicine, has been used for centuries to treat various diseases, including headaches and epilepsy. Recent studies have shown that GE possesses anti-inflammatory, antioxidant, and immunomodulatory properties. However, its effects on allergic asthma and airway remodeling have not been fully investigated.
Airway remodeling is a key feature of chronic asthma, involving structural changes such as goblet cell hyperplasia, subepithelial fibrosis, and smooth muscle hypertrophy. These changes contribute to irreversible airflow obstruction and decline in lung function. The development of airway remodeling is mediated by various inflammatory cytokines and growth factors, including TGF-β1. Therefore, targeting both inflammation and remodeling is crucial for effective asthma management. In this study, we evaluated the effects of GE extract on airway inflammation and remodeling in a mouse model of allergic asthma and explored the underlying molecular mechanisms.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, CHEN Jing (2025). Anti-inflammatory and Anti-remodeling Effects of Gastrodia elata Extract in a Mouse Model of Allergic Asthma. Chinese Journal of New Drugs. https://doi.org/cast_zgxyzz_1236731781425189256
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study demonstrates that Gastrodia elata extract reduces airway inflammation and remodeling in a mouse model of allergic asthma, likely by inhibiting NF-κB and STAT3 signaling pathways.
How was the asthma model induced in this study?
The asthma model was induced by sensitizing and challenging BALB/c mice with ovalbumin (OVA), a common allergen used to mimic allergic asthma.
What parameters were measured to assess airway remodeling?
Airway remodeling was assessed by measuring goblet cell hyperplasia, collagen deposition, and smooth muscle thickness in lung tissues.
What are the potential implications of this study?
The findings suggest that Gastrodia elata extract could be a potential therapeutic agent for allergic asthma, offering an alternative or complementary approach to current treatments.
What signaling pathways are involved in the anti-inflammatory effects of Gastrodia elata?
The anti-inflammatory effects are associated with the inhibition of NF-κB and STAT3 signaling pathways, which are key regulators of inflammatory responses.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.